| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/28/2004 | CA2522712A1 Nerve regenerating drug |
| 10/28/2004 | CA2522666A1 Combination therapies for chronic obstructive pulmonary disease (copd) |
| 10/28/2004 | CA2522471A1 Methods for the treatment of pain comprising opioid antagonists |
| 10/28/2004 | CA2522313A1 Combinations comprising paroxetine and 2-(s)-(4-fluoro-2-methyl-phenyl)-piperazine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoro-2-methyl-phenyl)-ethyl]-methyl amide for treatment of depression and/or anxiety |
| 10/28/2004 | CA2522311A1 Combinations of paroxetine and 4-(s)-(4-acetyl-piperazin-1-yl)-2-(r)-(4-fluoro-2-methyl-phenyl-piperidine-1-carboxylic acid [1-(r)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]methylamide for treatment of depression and / or anxiety |
| 10/28/2004 | CA2522298A1 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 10/28/2004 | CA2522297A1 Process for making gel films |
| 10/28/2004 | CA2522296A1 Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom |
| 10/28/2004 | CA2522294A1 Formulations and methods for treating rhinosinusitis |
| 10/28/2004 | CA2522293A1 Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom |
| 10/28/2004 | CA2522266A1 Phenylazole compound, production process therefor and antioxidant |
| 10/28/2004 | CA2522213A1 Semi-synthetic saponin analogs with carrier and immune stimulatory activities for dna and rna vaccines |
| 10/28/2004 | CA2522203A1 Identification of n-alkylglycine trimers for induction of apoptosis |
| 10/28/2004 | CA2522199A1 3-benzhydrylidene-8-aza-bicyclo¬3.2.1|octane derivatives with opioid receptor activity |
| 10/28/2004 | CA2522143A1 A pharmaceutical composition containing an active agent having the effect of digitalis and a cgmp phosphodiesterase inhibitor |
| 10/28/2004 | CA2522126A1 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes |
| 10/28/2004 | CA2522112A1 Solid preparation for oral use |
| 10/28/2004 | CA2522084A1 Cyclic amine derivatives and their use in the treatment of inflammation-related disorders mediated by bradykinin |
| 10/28/2004 | CA2522082A1 Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
| 10/28/2004 | CA2522080A1 N- (((((1,3-thiazol-2-yl) amino) carbonyl) phenyl) sulfonyl) phenylalanine derivatives and related compounds for the treatment of diabetes |
| 10/28/2004 | CA2522007A1 Methods of preventing or treating respiratory conditions |
| 10/28/2004 | CA2521991A1 Arthritis preventing or treating agent |
| 10/28/2004 | CA2521987A1 Methods and compositions for increasing the anaerobic working capacity in tissues |
| 10/28/2004 | CA2521972A1 Skin protection composition comprising an extract of sasa |
| 10/28/2004 | CA2521937A1 Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| 10/28/2004 | CA2521925A1 Preparation and purification of synthetic capsaicin |
| 10/28/2004 | CA2521842A1 Phosphate derivatives of pharmaceutical products |
| 10/28/2004 | CA2521841A1 Imidazole derivatives for treatment of allergic and hyperproliferative disorders |
| 10/28/2004 | CA2521839A1 Augmented cognitive training |
| 10/28/2004 | CA2521831A1 Benzoxepino-11-piperidylidene compounds and process for production thereof |
| 10/28/2004 | CA2521818A1 Fullerene compositions for ameliorating dermatological conditions |
| 10/28/2004 | CA2521810A1 Substituted quinobenzoxazine analogs |
| 10/28/2004 | CA2521808A1 Computer-based model for identification and characterization of non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors |
| 10/28/2004 | CA2521678A1 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 10/28/2004 | CA2521655A1 Abuse-resistant oral dosage forms and method of use thereof |
| 10/28/2004 | CA2521650A1 Interferon beta in severe acute respiratory syndrome (sars) |
| 10/28/2004 | CA2521649A1 Composition and uses of galectin antagonists |
| 10/28/2004 | CA2521619A1 Aminoquinoline compounds |
| 10/28/2004 | CA2521471A1 Methods of administering estrogens and progestins |
| 10/28/2004 | CA2521464A1 Irna conjugates |
| 10/28/2004 | CA2521462A1 Derivatives of azithromycin |
| 10/28/2004 | CA2521420A1 Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
| 10/28/2004 | CA2521394A1 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.o]non-1 (7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 10/28/2004 | CA2521381A1 Method for preparation of site-specific protein conjugates |
| 10/28/2004 | CA2521379A1 Pharmaceutical formulations containing methylnaltrexone |
| 10/28/2004 | CA2521369A1 The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome |
| 10/28/2004 | CA2521364A1 [c]-fused bicyclic proline derivatives and their use for treating arthritic conditions |
| 10/28/2004 | CA2521361A1 Chrono delivery formulations and method of treating atrial fibrillation |
| 10/28/2004 | CA2521313A1 Derivatives of 2-(8,9-dioxo-2,6-diazabicyclo(5.2.o)non-1(7)-3n-2-yl)-al kyl phosphonic acid and their use as n-methyl-d-aspartate (nmda) recetor antagonists |
| 10/28/2004 | CA2521189A1 Lysophosphatidic acid analogs and inhibition of neointima formation |
| 10/28/2004 | CA2521129A1 Pyrimidinone compounds as calcilytics |
| 10/28/2004 | CA2520805A1 Pyrrolo[1,2-b]pyridazine compounds and their uses |
| 10/28/2004 | CA2520323A1 Tie-2 modulators and methods of use |
| 10/28/2004 | CA2520262A1 Selectively inhibiting estrogen production and providing estrogenic effects in the human body |
| 10/28/2004 | CA2520020A1 Venlafaxine compositions comprising pellets with double layer coating |
| 10/28/2004 | CA2508636A1 Use of l-carnitine for the treatment of cardiovascular diseases |
| 10/28/2004 | CA2463487A1 Tumours treating combinations, compositions and methods |
| 10/28/2004 | CA2463464A1 Methods of treatment and compositions therefor |
| 10/27/2004 | EP1471146A2 A packaging cell line expressing for use in facilitating the development of high capacity adenoviral vectors |
| 10/27/2004 | EP1471141A1 Method for the production of resveratrol in cell cultures |
| 10/27/2004 | EP1471067A1 Derivatives of 2-oxothiadiazoline-4-carboxylic acid and its use as active photoprotective agent |
| 10/27/2004 | EP1471064A1 Coumarin derivatives, process for their production and use thereof |
| 10/27/2004 | EP1471063A1 Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis |
| 10/27/2004 | EP1471059A1 S-triazine derivatives having 3 particular para-aminobenzalmalonate groups ;sunscreen compositions containing these derivatives; and their use |
| 10/27/2004 | EP1471056A1 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 10/27/2004 | EP1471055A1 6-phenylpyridyl-2-amine derivatives |
| 10/27/2004 | EP1471054A1 Amino alcohol derivative or phosphonic acid derivative and medicinal composition containing these |
| 10/27/2004 | EP1471049A1 Novel thyroid hormone receptor ligand, medicinal compositions containing the same and use thereof |
| 10/27/2004 | EP1470826A1 Decoy-containing pharmaceutical compositions and method of using the same |
| 10/27/2004 | EP1470825A1 Reagents for detecting efavirenz |
| 10/27/2004 | EP1470823A1 Polymer-clay nanocomposite for extended release of active ingredient |
| 10/27/2004 | EP1470822A1 Method and composition for treating hypopigmentation of the hair and skin |
| 10/27/2004 | EP1470819A1 High drug load mesalazine sachet |
| 10/27/2004 | EP1470818A1 Use of piperazine phenothiazine derivatives in the manufacture of a medicament with neuroprotector and/or neurotrophic effects on cns and/or pns |
| 10/27/2004 | EP1470817A1 Compositions for preventing human cancer and method of preventing human cancer |
| 10/27/2004 | EP1470816A2 Once-a-day metoprolol oral dosage form |
| 10/27/2004 | EP1470815A1 Opiod formulations for treating pain |
| 10/27/2004 | EP1470257A2 RNA INTERFERENCE MEDIATED INHIBITION OF NF-KAPPA B/REL-A GENE EXPRESSION USING SHORT INTERFEREING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470256A2 RNA INTERFERENCE MEDIATED INHIBITION OF GASTRIC INHIBITORY POLYPEPTIDE /GIP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 10/27/2004 | EP1470249A2 Effectors of innate immunity |
| 10/27/2004 | EP1470246A2 Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| 10/27/2004 | EP1470240A2 Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 21656, 32427, 2402, 7747,1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165,2 |
| 10/27/2004 | EP1470239A2 Psoriasin expression by breast epithelial cells |
| 10/27/2004 | EP1470231A2 Methods of obtaining isoform specific expression in mammalian cells |
| 10/27/2004 | EP1470154A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 10/27/2004 | EP1470150A2 Corticosteroids nitrate derivatives |
| 10/27/2004 | EP1470148A2 Double-stranded oligonucleotides |
| 10/27/2004 | EP1470145A2 Methods and materials for modulating p2x2 |
| 10/27/2004 | EP1470144A2 Oligonucleotides comprising alternating segments and uses thereof |
| 10/27/2004 | EP1470143A1 Compounds that inhibit factor xa activity |
| 10/27/2004 | EP1470141A2 Glycosulfopeptide inhibitors and methods of use thereof |
| 10/27/2004 | EP1470139A2 NOVEL, WATER−SOLUBLE PORPHYRIN PLATINUM COMPOUNDS WITH HIGH TUMOR SELECTIVITY AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOR DISEASES |
| 10/27/2004 | EP1470138A1 Mmp inhibitors |
| 10/27/2004 | EP1470137A1 Edg receptor agonists |
| 10/27/2004 | EP1470131A2 Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| 10/27/2004 | EP1470130A2 Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno 2,3-b 1,5 benzodiazepine |
| 10/27/2004 | EP1470127A1 N, n'-dimethylated n-confused porphyrins |
| 10/27/2004 | EP1470126A1 N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| 10/27/2004 | EP1470125A1 Aminopiperidine derivatives |
| 10/27/2004 | EP1470124A1 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES |